Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509693 | 0.92 | IRAK4 (0.48) | HPGDALDH1A1CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL11169214 | 0.92 | KDM4E (0.50) | HPGDALDH1A1CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL1034425 | 0.89 | CYP1A2 (0.46) | HPGDALDH1A1CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL1032978 | 0.84 | BRD4 (0.44) | HPGDALDH1A1CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL1032977 | 0.84 | BRD4 (0.44) | HPGDALDH1A1CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL4705404 | 0.83 | UTS2R (0.40) | CYP2D6CYP3A4CYP1A2CYP2C19USP2 | |
| SCHEMBL31403002 | 0.81 | JAK3 (0.49) | CYP2D6CYP3A4HSD11B1HSD11B2IRAK4 | |
| SCHEMBL13003296 | 0.80 | ACHE (0.71) | LMNARAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL3335610 | 0.76 | GPR119 (0.54) | ALDH1A1CYP2D6CYP3A4NPC1RAB9A | |
| SCHEMBL31350706 | 0.74 | HPGD (0.53) | HPGDALDH1A1CYP2D6CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102321015-A | Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine | LIAONING DEFENG PHARMACEUTICAL CO LTD | 2012-01-18 | — | — | CN | claimed |
| JP-4209388-B2 | — | — | 2009-01-14 | — | — | JP | claimed |
| EP-1519936-B1 | METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS (US) | 2008-01-02 | — | — | EP | claimed |
| CN-1280293-C | Improved process for the preparation of nevirapine | BOEHRINGER INGELHEIM CHEMICALS (US) | 2006-10-18 | — | — | CN | claimed |
| JP-2005533083-A | — | — | 2005-11-04 | — | — | JP | claimed |
| CN-1653065-A | Improved method for making nevirapine | BOEHRINGER INGELHEIM CHEMICALS (US) | 2005-08-10 | — | — | CN | claimed |
| EP-1519936-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | Boehringer Ingelheim Chemicals, Inc. (US) | 2005-04-06 | — | — | EP | claimed |
| US-6680383-B1 | REACTING 2-HALO-3-PYRIDINECARBONITRILE WITH CYCLOPROPYLAMINE, THEN HYDROLYZING TO FORM 2-HALONICOTINIC ACID, AMIDATING AND CYCLIZING TO FORM DRUGS USED AS POLYMERASE INHIBITORS; VIRAL DISEASES | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-20 | — | — | US | claimed |
| WO-2004002988-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-20040002603-A1 | Method for making nevirapine | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-01 | — | — | US | claimed |
| CN-116675640-A | Preparation method of nevirapine intermediate 2- (cyclopropylamino) nicotinic acid | 中科苏州药物研究院 | 2023-09-01 | — | — | CN | disclosed |
| CN-110218211-B | Simple preparation method of nevirapine | 新发药业有限公司 | 2020-06-23 | — | — | CN | disclosed |
| WO-2016118586-A1 | LOWCOST, HIGH YIELD SYNTHESIS OF NEVIRAPINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016118586-A1 | LOWCOST, HIGH YIELD SYNTHESIS OF NEVIRAPINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-07-28 | — | — | WO | disclosed |
| CN-104774204-A | Methods for preparation of nevirapine and intermediate thereof | LUNAN BETTER PHARMACEUTICAL CO LTD | 2015-07-15 | — | — | CN | disclosed |
| US-6680383-B1 | REACTING 2-HALO-3-PYRIDINECARBONITRILE WITH CYCLOPROPYLAMINE, THEN HYDROLYZING TO FORM 2-HALONICOTINIC ACID, AMIDATING AND CYCLIZING TO FORM DRUGS USED AS POLYMERASE INHIBITORS; VIRAL DISEASES | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| WO-2004002988-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002988-A1 | IMPROVED METHOD OF MAKING NEVIRAPINE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20040002603-A1 | Method for making nevirapine | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20040002603-A1 | Method for making nevirapine | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002603-A1 | Method for making nevirapine | IDH1, IDH3B, CBR3 | HPGD 497/4885ALDH1A1 313/4885CYP2D6 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.